Annual Report 2024

CHAIRMAN’S STATEMENT 10 The United Laboratories International Holdings Limited Annual Report 2024 On 24 March 2025, the Company and The United Bio- Technology (Hengqing) Co., Ltd., a wholly-owned subsidiary of the Company have entered into an exclusive license agreement with Novo Nordisk A/S, a leading global healthcare company, in respect of the Group’s self-developed product UBT251. This is a significant milestone in the Group’s R&D progress. On behalf of the Board, I would like to take this opportunity to express my gratitude to our shareholders and partners from all sectors of society for their full trust and support in long time, as well as to our staff for their hard work and contributions. I hope we can join hands and create a better future together. Tsoi Hoi Shan Chairman Hong Kong, 24 March 2025